“Differential Response Between African Americans and Non-African Americans with Resistant Hypertension to MANP, a Novel Guanylyl Cyclase-A Receptor Activator: A Phase 1b Clinical Trial”
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced its presentation of clinical trial results at the 2025 Annual Meeting of the American College of Cardiology.
The presentation, “Differential Response Between African Americans and Non-African Americans with Resistant Hypertension to MANP, a Novel Guanylyl Cyclase-A Receptor Activator,” will be delivered by Horng H. Chen, M.D., Chair, Division of Circulatory Failure, Department of Cardiovascular Medicine at Mayo Clinic, and Principal Investigator of the referenced clinical trial.
E-Star has licensed MANP from Mayo Clinic and is currently studying the drug in the Bold-HTN Study, a Phase 2 study To Evaluate the Safety and Efficacy of MANP in Subjects with Difficult to Control/Resistant Hypertension (https://clinicaltrials.gov/study/NCT06343298).
E-Star recently announced that it has dosed its first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension (BOLD-HTN).
MANP was originally discovered by John C. Burnett Jr., M.D., Director of the Cardiorenal Research Laboratory at Mayo Clinic. E-Star and Mayo Clinic entered into a worldwide exclusive license agreement for the development of MANP in cardiovascular and metabolic indications in 2021. With the support of $36 million in grants and seed-stage private investment, MANP has demonstrated a strong safety profile in multiple Phase 1 studies of participants with hypertension, resistant hypertension, and hypertension with comorbid cardiometabolic syndrome.
An estimated 1.28 billion adults aged 30-79 years old suffer from hypertension worldwide. While scores of drugs are available to treat hypertension, only 1 in 5 adults (approximately 21%) with hypertension gain control of their condition. Hypertension remains a leading driver of premature death in both developed and developing countries. E-Star is dedicated to bringing the remaining 79% of hypertension patients under control and reducing the burden of premature death.
About E-Star BioTech, LLC
E-Star is developing a platform of Natriuretic Peptides for the treatment of metabolic syndrome. The Company’s lead asset, MANP, is currently being investigated in a Phase 2 clinical trial. To learn more, please visit: https://www.e-star.bio/.
Contact:
LR Advisors
Jason Assad
678-570-6791
Access to an audience of over 19 million individuals monthly will expand national exposure, and…
NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…
AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…
Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…
Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…
Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…